Study Also Shows 36% Reduction in Risk of Heart Attack
Repatha is the First and Only PCSK9 Inhibitor to Significantly Reduce the Risk of First Heart Attack and Stroke
Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha® (evolocumab) achieved statistically significant and clinically meaningful reductions in major adverse cardiovascular events (MACE) in high-risk adults without a prior heart attack or stroke, when added to statins or other low-density lipoprotein cholesterol (LDL-C)–lowering treatments. Repatha is the first and only PCSK9 inhibitor to demonstrate a significant reduction of cardiovascular events as both high-risk primary and secondary prevention. The results were presented in a late-breaking session at the 2025 American Heart Association Scientific Sessions and simultaneously published in the New England Journal of Medicine.
https://finance.yahoo.com/news/amgens-repatha-cuts-risk-first-151000799.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.